ParaZero Strengthens Global Sales Leadership with Appointment of Bat-Sheva Noy as VP
Rhea-AI Summary
ParaZero (Nasdaq: PRZO) appointed Bat-Sheva Noy as Vice President of Global Sales, effective March 4, 2026. Ms. Noy brings over 20 years of commercial leadership, including roles at Pfizer Israel and GSK Israel, and holds an LL.B. and a B.Sc. Her experience targets expansion of ParaZero's global commercial presence in drone safety and aerospace.
Positive
- None.
Negative
- None.
Market Reaction – PRZO
Following this news, PRZO has declined 6.72%, reflecting a notable negative market reaction. Our momentum scanner has triggered 8 alerts so far, indicating moderate trading interest and price volatility. The stock is currently trading at $1.25. This price movement has removed approximately $2M from the company's valuation.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
PRZO’s move contrasted with momentum scanner data showing the stock trending down while peers like CVU and KITT appeared in momentum screens moving up, and sector peers showed mixed price changes (e.g., XTIA up 23.47%, KITT down 5.33%). This points to stock-specific trading around the leadership news rather than a uniform Aerospace & Defense move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 20 | Defense order expansion | Positive | +1.7% | Additional DefendAir Counter‑UAS order from a second Israeli defense branch. |
| Feb 18 | Test performance update | Positive | +6.9% | DefendAir internal live test intercepting a 70 mph hostile drone. |
| Feb 09 | Trade fair participation | Positive | +3.9% | Announcement to showcase DefendAir at Enforce Tac 2026 in Germany. |
| Jan 30 | Follow-on defense order | Positive | -6.6% | Second substantial order for operational interception net-pods from global defense firm. |
| Jan 27 | European reseller deal | Positive | +5.0% | New reseller agreement and initial DefendAir training kit order in NATO country. |
Recent operational and contract announcements have generally seen positive price reactions, with one notable divergence on a substantial follow-on order.
Over the past months, ParaZero has reported multiple DefendAir milestones, including new reseller agreements in NATO-aligned European markets, repeat orders from a major global defense corporation, and additional orders from Israeli defense entities, each often followed by positive one-day price reactions of up to 6.86%. One substantial follow-on order on Jan 30, 2026 coincided with a -6.61% move, showing occasional divergence. Today’s senior sales hire fits into this broader commercial expansion narrative.
Market Pulse Summary
The stock is down -6.7% following this news. A negative reaction despite a seasoned sales leader joining would fit prior instances where strong operational updates did not uniformly support the share price, such as the -6.61% move after a substantial follow-on order. Investors tracking this pattern might note that, while commercial traction and leadership depth have expanded, past financing and execution risks have at times overshadowed otherwise constructive announcements.
Key Terms
uas technical
electro-optics technical
AI-generated analysis. Not financial advice.
Kfar Saba, Israel, March 04, 2026 (GLOBE NEWSWIRE) -- ParaZero Technologies Ltd. (Nasdaq: PRZO) (the “company” or “ParaZero”), an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry, recently announced the appointment of Bat-Sheva Noy as its new Vice President of Global Sales.
Ms. Noy brings more than 20 years of extensive commercial and leadership experience, with particular expertise in strategic planning, market access, and leading cross-functional teams. Most recently, from 2020 to 2025, she served as the Business Unit Lead for Rare Diseases at Pfizer Israel (a subsidiary of Pfizer Inc., NYSE: PFE). In that role, she was responsible for developing and executing strategy, building and developing teams, and driving overall business performance in the rare diseases portfolio.
Prior to that position, she held the role of Sales and Marketing Lead at Pfizer Israel from 2017 to 2019, where she oversaw national sales and marketing operations specifically for the company's cardiovascular product lines.
Her earlier career at Pfizer Israel spanned 2004 to 2017, during which she held various sales and managerial positions. Before joining Pfizer, she worked as a sales representative at GSK Israel from 2002 to 2004.
Educationally, Ms. Noy holds an LL.B. in Law from The Academic Centre of Law and Science in Israel, as well as a B.Sc. in Chemistry and Biology from Tel Aviv University. She also served in the Israel Defense Forces (IDF) as an optical systems instructor in the electro-optics unit.
ParaZero Technologies believes that Ms. Noy's deep experience and leadership background are key strengths that she will bring to the role, supporting the company's efforts to expand its global commercial presence in the growing drone safety and aerospace sector.
About ParaZero Technologies
ParaZero Technologies Ltd. (Nasdaq: PRZO) is an aerospace defense company pioneering smart, autonomous solutions for the global manned and unmanned aerial systems (UAS) industry. Founded in 2014 by aviation professionals and drone industry veterans, ParaZero is a recognized leader in advanced drone technologies, supporting commercial, industrial, and governmental operations worldwide. The company’s product portfolio includes SafeAir, an autonomous parachute recovery system designed for aerial safety and regulatory compliance; DefendAir, a counter-UAS net-launching platform for protection against hostile drones in both battlefield and urban environments; and DropAir, a precision aerial delivery system. ParaZero’s mission is to redefine the boundaries of aerial operations with intelligent, mission-ready systems that enhance safety, scalability, and security. For more information, visit https://parazero.com.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, ParaZero is using forward-looking statements when it discusses expanding its global commercial presence in the growing drone safety and aerospace sector. Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain. Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s Annual Report on Form 20-F filed with the SEC on March 21, 2025. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. ParaZero is not responsible for the content of third-party websites.
Investor Relations Contact:
Michal Efraty
Investor Relations
michal@efraty.com
FAQ
Who is Bat-Sheva Noy and what role did ParaZero (PRZO) appoint her to on March 4, 2026?
What relevant experience does Bat-Sheva Noy bring to ParaZero (PRZO) from Pfizer and GSK?
How might Bat-Sheva Noy's appointment affect ParaZero's (PRZO) global commercial strategy?
What are Bat-Sheva Noy's educational and military backgrounds noted by ParaZero (PRZO)?
When did Bat-Sheva Noy serve as Business Unit Lead for Rare Diseases at Pfizer Israel prior to joining ParaZero (PRZO)?
